Cleared Special

K222234 - GlucoSure ADVANCE Link Blood Glucose Monitoring System

K222234 is an FDA 510(k) clearance for GlucoSure ADVANCE Link Blood Glucose Mo..., manufactured by Apex BioTechnology Corp.. The device is a Class 2 Chemistry device with product code NBW cleared through the Special 510(k) pathway after a 148-day FDA review.

K222234 · Apex BioTechnology Corp. · Chemistry device
Download Printable Device Report (PDF) Official FDA 510(k) Summary (PDF)
Optimized for regulatory review, auditing and printing
Dec 2022
Decision
148d
Days
Class 2
Risk

K222234 is an FDA 510(k) clearance for the GlucoSure ADVANCE Link Blood Glucose Monitoring System. Classified as System, Test, Blood Glucose, Over The Counter (product code NBW), Class II - Special Controls.

Submitted by Apex BioTechnology Corp. (Hsinchu, CN). The FDA issued a Cleared decision on December 21, 2022 after a review of 148 days - within the typical 510(k) review window.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.1345 - the FDA in vitro diagnostics and chemistry framework. As a Special 510(k), this submission covers a manufacturer modification to an existing cleared device rather than a new device introduction.

Device pattern: Iterative device modification. Standard predicate reliance. This Special 510(k) clearance confirms that the manufacturer's modifications remained within the established regulatory envelope of the original cleared device.

FDA 510(k) Submission Details - K222234

510(k) Number K222234 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received July 26, 2022
Decision Date December 21, 2022
Days to Decision 148 days
Submission Type Special
Review Panel Chemistry (CH)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
59d slower than avg
Panel avg: 89d · This submission: 148d
Pathway characteristics
Modification to existing cleared device.

NBW Device Classification - Class 2, Special Controls

Product Code NBW System, Test, Blood Glucose, Over The Counter
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.1345
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Chemistry devices follow this clearance model.

Regulatory Peers - NBW System, Test, Blood Glucose, Over The Counter

All 513
Devices cleared under the same product code (NBW) and FDA review panel - the closest regulatory comparables to K222234.
Accu-Chek Guide Solo diabetes manager blood glucose monitoring system
K213131 · Roche Diabetes Care GmbH · Aug 2023
ReliOn Premier BLU Blood Glucose Monitoring System
K230625 · I-Sens, Inc. · Aug 2023
MIO Blood Glucose Monitoring System
K223722 · Mio Labs, Inc. · Jun 2023
CONTOUR® NEXT GEN Blood Glucose Monitoring System
K223293 · Ascensia Diabetes Care U.S., Inc. · Nov 2022
BGM039 Blood Glucose Monitoring System, BGM039 Link Blood Glucose Monitoring System
K220421 · Apex BioTechnology Corp. · Nov 2022
SuperCheck Pro Blood Glucose Monitoring System
K213061 · Ok Biotech Co., Ltd. · Oct 2022
K222234 · GlucoSure ADVANCE Link Blood Glucose Monitoring System
Download PDF FDA Summary Apex BioTechnology Co…